- Date 28 May 2014
- Documents : 4
- History
- (Restricted access link)
Listen
Reason for request
Re-assessment of the Actual Benefit of all medicines indicated for menopausal hormone replacement therapy at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code and Renewal of inclusion for ESTREVA scored tablet and ESTREVA 0.1% gel
-
Clinical Benefit
| Substantial |
The actual benefit of the proprietary medicinal products ESTREVA scored tablet, 0.1% gel and FEMSEPT 50 μg/24 hours, 75 μg/24 hours, 100 μg/24 hours in hormone replacement therapy (HRT) for symptoms of oestrogen deficiency in menopausal women remains substantial in patients for whom climacteric disorders are described as troublesome enough to impair their quality of life when these proprietary medicinal products are used as per the Committee's recommendations.
|
Therapeutic use
- |
